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Abstract
Background: Dietary salt consumption is an important factor for mortality from cardiovascular diseases (CVDs). Therefore, the aim 
of this study is to measure the levels of salt consumption and then estimate the effects of current levels of salt consumption on 
mortality from CVDs at national and subnational levels from 1990 to 2016 in Iran.
Methods: In this study, we will use national and subnational studies with data on salt consumption, including self-report or lab 
tests for sodium measurement and all available published data about salt and sodium (with conduct a systematic review) to 
estimate salt exposure levels. We will also use data from death registration system (DRS) to estimate CVDs mortality attributable 
to salt consumption. We will use mixed-effects model to explore the effects of some covariates on salt consumption and then 
spatial-temporal model will be used to take into account how the values of salt consumption in each point vary further across 
time, space, and age. We will compute the proportional reduction in CVD deaths that will occur if salt consumption reduces to an 
alternative level (5 g/d), using comparative risk assessment (CRA). The simulation analysis will be used to estimate the uncertainty 
of the number of deaths attributable to salt consumption. All analyses will be performed separately by sex in STATA and R software 
packages.
Conclusion: The findings of this study seem to be helpful for providing good information about the salt consumption and CVDs 
mortality attributable to it for policymakers in directing future policy decisions and planning cost-effective strategies in Iran.
Keywords: Cardiovascular diseases, Mortality, Salt, Sodium
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Introduction
Dietary salt consumption is an important determinant 
of  individual and population levels of  blood pressure.1 
Reducing dietary salt consumption reduces blood pressure 
and consequently lowers the risk of  cardiovascular 
diseases (CVDs).2,3 In this setting, in a global study, 
Mozaffarian et al reported that 1.65 million annual deaths 
due to cardiovascular events, including 7034 from Iranian 
population, were attributed to salt consumption above 
the 5 g/d (reference level).4 Also, some studies observed 
that dietary salt intake is directly associated with risk of 
gastric cancer.5–7 Other studies reported the association 
between sodium consumption and renal function and 
proteinuria8–13 in patients with CVDs at baseline. High 
salt consumption can be a key factor which could increase 
morbidity and mortality of  non-communicable diseases 
(NCDs) in developed and developing countries. Iran, 
as a developing country, is facing a rapid increase in the 
burden of  NCDs14 and a part of  this increase might be 
due to high salt consumption in Iran. According to Nazeri 
and colleagues’ study conducted in Tehran, the mean per 
capita daily salt consumption was 9.5 g.15 Another study 
on adults aged 20–74 years from Yazd city indicated that 
the estimated mean per capita daily salt consumption 
were 10.04 g/d for males and 7.47 g/d for females.16 
There have also been dietary salt studies that used food 
frequency questionnaires to estimate salt consumption 
and these studies estimated that the average salt 
consumption for the population aged 2–79 was 10.3 g/d 
in Ilam, 7.7 g/d in Sari and 7.2 g/d in Rasht.17,18 All above 
mentioned estimations depict that salt consumption of 
Iranians is high and varies from one province to another. 
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Yet, the national effects of  salt consumption and the 
heterogeneity of  these effects according to age, sex, 
and geographic have not been clearly established. So we 
intend to measure the levels of  salt consumption and then 
estimate the effects of  current levels of  salt consumption 
on mortality from CVDs at national and subnational levels 
from 1990 to 2016 in Iran. The study is a sub-component 
of  the NASBOD study.19–24 The current paper provides 
information on data sources and methods that we are 
using for estimating salt consumption exposure and its 
attributable death due to CVDs.
Materials and Methods 
Overview
In this study, we will use all related and available data 
sources, including national and subnational studies with 
data on salt consumption, including self-report or lab 
tests for sodium measurement and all available published 
data about salt and sodium to estimate salt exposure 
levels. We will also use data from death registration 
system (DRS) to estimate CVDs mortality attributable to 
salt consumption. Analyses will be performed separately 
by sex and results will be provided by sex, age, province 
and year.
Process of  Study
This study contains 11 steps: 
1) Conducting a systematic review to collect published 
articles about salt or sodium whose studies were 
performed between January 1990 to December 2016 
in Iran.
2) Gathering data from all national and subnational 
(provincial, district and community) epidemiologic 
studies from January 1990 to December 2016 that 
have data on salt or sodium consumption or urinary 
sodium in population level through communication 
to studies managers.
3) Data preparation.
4) Statistical analysis.
5) Effect size estimation of  salt reduction on systolic 
blood pressure (SBP).
6) Effects size estimation of  SBP on deaths from 
CVDs.
7) Setting reference levels of  salt consumption.
8) Using SBP levels by national and subnational, age, 
sex from 1990 to 2016 that are prepared in another 
project in Iran.
9) Preparing cause-specific mortality data by national 
and subnational, age, sex from 1990 to 2016.
10)  Estimating population attributable fraction (PAF) 
of  salt consumption for CVDs, at national and 
subnational levels, by age and sex from 1990 to 2016.
11) Uncertainty calculation for all summary measures.
1. Conducting a Systematic Review to Collect Published 
Articles About Salt or Sodium 
Data Sources
We will conduct a systematic review of  the literature 
through searching online international electronic 
databases (PubMed, ISI Web of  Science, and Scopus), 
and national electronic databases (scientific Information 
Database [SID], IranMedex and Irandoc). 
Search Strategy
We will search the medical literature between January 
1990 and September 2017, using international and 
national digital databases to find all published articles 
whose studies were performed between January 1990 
to December 2016 in Iran. So, we will search the 
international databases for papers with any of  the search 
terms of  interest in the title or abstract that are extracted 
from the medical subject headings (MeSH) of  PubMed 
and Emtree of  Embase. Also, our searches will be 
limited to a given time period (between 1990 and 2017), 
to Iran, to human subjects with no language restriction. 
More details of  the search strategy are available in online 
Supplementary file 1. For search in national databases 
(SID, IranMedex and Irandoc), we will use the Persian 
search terms that are equivalent to their English search 
terms. In addition, we will consider national registration 
systems, and national and subnational surveys (Table 1).
Study Selection Process
In this study, we will perform three steps for selection of 
papers. First, the titles of  selected papers will be separately 
evaluated by two reviewers (The discrepancy between 
reviewers will be resolved through consensus). Second, 
the abstracts of  selected papers will be reviewed by them, 
and if  they agree that the article is not concordant with 
inclusion criteria (Table 2), the paper will be excluded. 
Third, the full text of  selected papers will be extracted 
and reviewers will check papers using standard criteria 
(the discrepancy between reviewers will be resolved 
through consensus and use of  a research specialist).
Quality Assessment Process
We will use the National Institute of  Health (NIH) quality 
assessment forms to evaluate the quality of  papers.25 The 
NIH quality assessment forms are provided based on 
study design (cohort, case-control, cross-sectional and so 
on). These forms include items for assessing potential 
flaws in study methods or implementation, including 
sources of  bias, confounding, study power, the strength 
of  causality, and other factors. All selected papers will 
be independently rated for quality by two reviewers 
using the appropriate form. Quality reviewers may select 
“yes,” “no,” or “cannot determine/not reported/not 
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applicable” in response to each item on the form. If  the 
ratings differ, then reviewers discuss the paper to reach 
consensus. Otherwise, the paper will be forwarded to a 
methodologist for quality adjudication. 
Data Extraction
In this stage, information from selected papers will 
be extracted and inserted in data extraction sheet 
independently by two researchers (The differences 
between them on the extracted data will be rechecked and 
resolved). Authors of  studies that have not demonstrated 
the related data will be contacted (via e-mail or telephone 
for 3 times) to request the data. In case of  non-
cooperation, the paper will be deleted. Data extraction 
sheet includes general information and data information 
that are shown in Table 3. In brief, the necessary data 
Table 1. National and Subnational Surveys From 1990 and 2016 Among Iranian Population
Survey (Abbreviation) Year Study Province
Household Income & Expenditure survey (HIEs) 2004–2016 All provinces of Iran
Comprehensive Project on Household Food Pattern and Nutritional Status 
First survey:1991-1995
Second survey:2000-2002
All provinces of Iran
Non-Communicable Disease Surveillance Survey (NCDSS) 
First survey: 2005
Second survey: 2006 
Third survey: 2007
Fourth survey: 2008
Fifth survey: 2009 
Sixth survey: 2011
Seventh survey: 2016
All provinces of Iran
The Tehran Lipid and Glucose Study (TLGS) 
Phase I: 1999–2000
Phase II: 2001–2004
Phase III: 2005–2008
Phase VI: 2009–2011
Phase IV: 2012–2015
Tehran
Isfahan Healthy Heart Program (IHHP)
Phase I: 2000–2001 
Phase II: 2001–2005 
Phase III: 2006–2007
Isfahan
Isfahan salt study
Phase I: 1998
Phase II: 2001
Phase III: 2007
Phase VI: 2013
Isfahan
Persian Gulf Healthy Heart Study (PGHHS)  2003–2004 Boshehr
Mashad Study 2007–2008 Razavi Khorasan
Kerman Coronary Artery Disease Risk study (KERCARD) 2009–2011 Kerman
Yazd Healthy Heart Program (YHHP) 2003–2004 Yazd
Urban Health Equity assessment and Response Tool (Urban Heart-phase1) 2007 Tehran
Golestan Cohort Study (GCS) 2004–2012 Golestan
Kavar Cohort 2006 Fars 
Shiraz Healthy Heart Cohort 2013 Fars
Zanjan Healthy Heart Cohort Zanjan
Urban Health Equity assessment and Response Tool (Urban Heart-phase2) 2011 Tehran
Nutritional Knowledge, Attitude and Practice of Rural and Urban Iranian Household as 
well as Health Practitioners in three provinces (Pilot study) and NUTRIKAP Survey
2004, 2012
Bushehr, Sistan and Baloochestan
And Golestan provinces
National Health Survey (NHS) 1999 All provinces of Iran
Table 2. Article Inclusion and Exclusion Criteria
Criteria Additional Information
Including
Date 1st Jan 1990 to 31th Dec 2016
Age group Covering ≥ 35 years in groups 35–44, 45–54, 55–64, 65–74, 75–84 and ≥ 85 years of age
Gender Both male and/or female
Measurement indicator Salt or sodium consumption or urinary sodium
Type of data gathering source Population sources
Excluding
Date Before 1st Jan 1990
Age group Not covering ≥ 35 years of age
Type of data gathering source Not mentioned as population sources
Study design Any study such as cohort studies without population base data, hospital case-controls, case reports, case series, and also 
the studies that surveyed special populations (such as immigrants, specific employees, patients and volunteers), clinical 
trial studies, comparing studies like ethnic based, interventional studies.
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include mean, standard deviation (SD), standard error 
(SE) of  mean and confidence interval (CI) for salt or 
sodium consumption or urinary sodium excretion by 
year, province, sex and age group. 
2. Gathering Data From National and Subnational Based 
Studies
In this study, we will include all national and subnational 
based studies from January 1990 to December 2016 that 
have surveyed the salt/sodium consumption or urinary 
sodium in population level. Our target population is 
healthy Iranian adult population (≥35 years) living in Iran 
from 1990 to 2016. Hospital case-controls and studies 
that surveyed special populations (such as immigrants, 
specific employees, patients and volunteers) will be 
excluded. The epidemiologic studies at national and 
subnational levels include Tehran Lipid and Glucose 
Study (TLGS), Golestan Cohort Study (GCS), non-
communicable disease surveillance survey (NCDSS) and 
other studies that are mentioned in Table 1. 
3. Data Preparation 
In this step, we will consider all prepared data points 
from selected articles and national and subnational 
Table 3. Data Extraction Form
A: General Information
(I) Article code: The number of article in the folder. It begins from 1.
(II) Study code: The number of the survey in the article. It begins from 1.
(III) Article ID: For PubMed articles “PMID” and for ISI articles “DOI” will be recorded.
If the study has a special name, it is written in the “Study name” column.
(IV) Publication date: It refers to the year that article has been published
(V) Corresponding author ‘s characteristics: Including the first name, family name and e-mail address
(VI) Study source
1. Iranian databases, 2. Foreign databases, 3. Non-indexed Iranian journals, 4. Health surveys, 5. Abstract of congress, 6. Theses, 7. Other un-published 
reports
(VII) Study setting
1. Rural, 2. Urban, 3. Both
(VIII) Level of study
1. National, 2. Provincial, 3. District, 4. Community, 5. Sub-region (2 or more provinces with similar ethnicity and race), 6. Two or more sub-regions
(VIIII) Sampling unit
1. Individualized data, 2.Household data
(X) Sampling method
1. Multi-level clustering random sampling, 2. One-level clustering random sampling, 3. Simple random sampling, 4. Others
(XI) Sample weight (The target group proportionates to Iran population’s sex and age)
1. No, 2. Yes
B: Data information
(I) Age of participants: 
Min:       Max:     Mean:      SD:      Median:
(II) Sex:
1. Male, 2. Female, 3. Both
(III) Sample size: The sample size in each sex and age group of the study population.
(IV) Response rate: It refers to percentage of reported in Survey Info document or published manuscript
(V) Type of data
1. Intake (or consumption) data, 2. Expenditure data, 3. Other
(VI) Data collection year (start and end)
(VII) Diet Assessment Method
1. Multiple (≥ 2) short-term (up to 1 week) diet recalls/ records with correction for within-person variation
2. Multiple (≥ 2) short term (up to 1 week) diet recalls/ records without correction for within-person variation
3. FFQs, food surveys or household surveys
4. Single short-term diet recalls/records
5.  other, please specify
(VIII) Data collection technique
1. Personal interview
2. Telephone interview
3. Self-administered questionnaire
(VIIII) Method of food record
1. Weighting
2. Non-weighting
(X) Questionnaire validation
1. Yes, 2. No
(XI) Dietary sodium
1. Total dietary sodium intake from all dietary sources (Optimal)
2. Total urinary sodium (First alternative)
3. Total salt intake (Second alternative) 
Data extracted by, and data cross-checked by: The name of people who will extract and cross-check the data.
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studies. In this context, data will be converted into 
a form suitable for further analysis and processing. 
Therefore, we will have data points based on year and 
province of  data collection, sex and different age groups. 
We might encounter different methods for salt/sodium 
measurements. We will deal with this situation by using 
cross walking between obtained values of  salt/sodium 
in different methods using regression models. Then, 
we will provide a frame that includes years of  study 
(1990–2016), provinces of  study (31 provinces in Iran), 
sex (male-female) and age groups (6 age groups: 35–44, 
45–54, 55–64, 65–74, 75–84 and ≥85) and will merge 
prepared data to this frame. Sodium excreted from 24-
hour urine captures ~90% of  dietary sodium26 and the 
remainder is excreted via sweat, intestinal fluids, and 
saliva; therefore, we will add 10% to sodium values that 
are converted from 24- hour urinary sodium. To convert 
dietary sodium consumption to salt consumption, we will 
multiply sodium consumption by 2.54.
4. Statistical Model 
Despite our extensive search and attempt to access 
all national surveys, there might be some provinces 
without data or without provincial representative data 
in some years of  the study. Furthermore, all age groups, 
both sex, and all study’s years have not been included 
in some surveys (without data). To overcome this 
problem, we will use advanced statistical methods and 
proxy covariates to estimate data for without data points. 
To estimate mean (whatever the measure is) and its 
uncertainty interval by sex, age, year, and province, linear 
mixed-effect, spatio-temporal models and simulation 
analysis will be developed. Therefore, we will use mixed-
effects model to explore the effects of  some covariates 
on salt consumption and then we will predict it for all 
data points. Also, we will calculate the residuals of  salt 
consumption (predicted - observed) for each data point 
in mixed-effects model. Then, spatial-temporal model 
will be used to take into account how the values of  salt 
consumption in each points vary further across time, 
space, and age. The spatio-temporal model uses residuals 
(as valuable information) to predict new points data. 
Moreover, to combine incompatible areal units between 
data sources and/or over the years, spatio-temporal 
misalignment modeling will be used. The simulation 
analysis will be used to estimate the uncertainty interval 
for salt consumption. All statistical analyses will be 
conducted in STATA and R software packages.
5. Effect Size Estimation of  Salt Reduction on Systolic 
Blood Pressure 
Three recent meta-analyses assessed the effect of 
sodium reduction on BP,2,4,27 among which Mozaffarian 
and colleagues’ study is the newest and most detailed 
meta-analysis that assessed 103 trials that included 107 
randomized group comparisons (6970 subjects).4 This 
study observed a strong evidence for a linear effect of 
sodium reduction on blood pressure (BP) (P-linearity < 
0.001).
The final meta-regression equation of  Mozaffarian and 
colleagues’ study was 
Y = α+ B1X1 + B2X2 + B3X3
Where, Y = the BP change in each trial in mm Hg 
(standardized to a sodium reduction of  100 mmol/d 
(5.85 g/d salt consumption);
B1 = the mean age of  individuals in each trial in years 
(centered at age 50); 
B2 = whether the trial was conducted on normotensive 
or hypertensive individuals; 
B3 = whether the trial was conducted on non-Blacks or 
Blacks; and 
α = the effect of  a 100 mmol/d sodium (5.85 g/d salt 
consumption) reduction on SBP when mean subject 
age=50, individuals were normotensive, and individuals 
were not Black.
The final coefficients were: α = -3.735; B1 =- 0.105; B2 = 
-1.874; and B3 = -2.489.
We will use this equation in the present study. But β3 will 
be considered zero because this study will be conducted 
on non-Black people.
We will use STEPwise approach to surveillance of  non-
communicable diseases (STEPS) surveys to determine 
the percentage of  hypertensive individuals. The STEPS 
surveys were conducted in 2005–2009, 2011 and 2016 in 
Iran. We will interpolate and extrapolate to estimate the 
percentage of  hypertensive individuals in years without 
data. Then, we will use above regression formula in males 
and females with or without hypertension, separately. 
Then, weighted average will be used to combine the 
results.
6. Effects size estimation of  SBP on deaths from CVDs
In two prior pooling projects (the Prospective 
Studies Collaborative [PSC] and the Asia Pacific Cohort 
Studies Collaborative [APCSC]),28,29 the dose-response 
relationship between BP and CVD mortality has been 
established. These studies pooled data from 99 cohorts 
(1.38 million participants, and 65 000 cardiovascular 
events). The analyses of  these studies demonstrate a 
proportional dose-response relationship between SBP 
and CVDs at any age. According to this evidence, we 
will assume a proportional dose-response between SBP 
and CVDs until a SBP level of  115 ± 6 mm Hg (lower 
from this level we will assume no further contribution 
to risk). In Singh’ study to incorporate data from PSC 
and APCSC projects, the authors interpolated and 
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extrapolated age-specific relative risks of  SBP on CVDs 
mortality in 10-year age groups across the studies.30 We 
will use these age-stratified relative risks in our study.
7. Setting Reference Levels of  Salt Consumption
The reference level of  sodium (salt) consumption will 
be selected based on the observed consumption levels 
associated with lowest SBP in ecologic studies and in 
randomized trials and with lowest disease risk in meta-
analyses of  prospective cohort studies. According to the 
type of  disease and study, the reference levels of  sodium 
consumption are shown in Table 4. In ecologic studies, 
the lowest mean consumption level associated with both 
lower SBP and lower age-SBP was 614 mg/d.31 The 
lowest surveyed consumption level associated with SBP 
reductions in randomized trials was 1500 mg/d.32 Also, 
the lowest mean consumptions associated with lower 
risk of  CVDs events in prospective observational studies 
ranged from 1787 to 2391 mg/d.33 For this study which 
will focus on CVDs, we will use a conservative reference 
level of  sodium 2.0 ± 0.2 g/d (salt = 5 ± 0.5 g/d) that 
is consistent with mean intakes in several countries, and 
with the World Health Organization (WHO) guidelines.34
8. Using SBP Levels by National and Subnational, Age, 
Sex From 1990 to 2016
In another study, we obtained data for SBP from published 
papers, unpublished health examination surveys and 
epidemiological studies from different regions of  Iran. 
We used linear mixed-effect and spatio-temporal models 
to estimate mean of  SBP and its uncertainty interval by 
sex, age, year and province accounting for whether each 
study was provincially representative. 
 
9. Prepare Cause-Specific Mortality Data by National and 
Subnational, Age, Sex From 1990 to 2016
National and subnational death data reported by DRS 
will be included in this study to measure the CVD 
mortality based on age group and sex from 1990 to 2016. 
To overcome incompleteness of  the DRS, we will use the 
mortality section of  the NASBOD study.20 For this study, 
we will use data on deaths due to ischemic heart disease, 
ischemic stroke and other CVD (hemorrhagic stroke, 
hypertensive heart disease, aortic aneurysm, rheumatic 
heart disease, inflammatory heart disease and other 
CVDs). In this study, we will consider only SBP effects 
on deaths due to the above diseases.
10. Estimating PAF of  salt consumption for CVDs, at 
national and subnational levels, by age and sex from 1990 
to 2016
In this study, we will estimate salt consumption attributed 
burden using comparative risk assessment (CRA).35 This 
analysis (CRA) captures demographic and geographic 
variations in salt consumption, blood pressure, CVDs 
mortality, and their uncertainties. We will incorporate 
each province (subnational), age-specific, and sex-specific 
salt consumption, BP level, relative risk, and mortality 
data to estimate the fraction and numbers of  deaths 
from CVDs attributable to salt consumption above the 
reference level. 
In this study, we will compute the proportional reduction 
in CVD deaths that will occur if  salt consumption is 
reduced to an alternative level (5 g/d). This is known as 
the population-attributable fraction (PAF) and measures 
the total effects of  salt consumption. The PAF is 
calculated in 2 steps: (1) based on the age-, hypertensive-, 
and sex-specific BP effects of  salt consumption to 
calculate the change in mean SBP that would be expected 
from reducing salt consumption to a reference level (5.0 
± 0.5 g/d); (2) based on the age-specific effects of  SBP 
on CVDs to compute the resulting change in CVDs risk. 
We will compute PAF using the following equation: 
∫
∫ ∫
=
= =
−
= m
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m
x
m
x
xdxPxR
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0 0
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Table 4. The Reference Levels of Sodium Consumption According to Type of Disease and Study
Mean Intakes Outcomes Type of Study
1 614 mg/d Lower systolic BP and lower age-BP slopes Ecologic studies31
2 1245 mg/d Lower incidence of gastric cancer Meta-analysis of prospective cohorts45
3 1500 mg/d Reduced BP Randomized controlled trials32
4 2391 mg/d Lower incidence of total stroke Meta-analysis of prospective cohorts33
5 2245 mg/d Lower incidence of stroke mortality Meta-analysis of prospective cohorts33
6 1787 mg/d Lower incidence of CHD mortality Meta-analysis of prospective cohorts33
Mean Intakes Major Dietary Guidelines
1 < 1500 mg/d American Heart Association46
2 < 1200 mg/d UK National Institute for Health and Clinical Excellence, 2025 target47
3 < 1500 mg/d US Dietary Guidelines Advisory Committee48
4 < 2300, <1500 mg/d US Dietary Guidelines for Americans49
5 < 2400 mg/d UK Food Standards Agency50
6 < 2000 mg/d World Health Organization51
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Where x = current SBP level; P(x) = actual distribution 
of  SBP at current salt consumption in the population; 
P’(x) = alternative distribution of  SBP if  salt consumption 
were at the alternative reference distribution in the 
population; RR(x) = the (age-specific) relative risk of 
each SBP-related disease for a unit change in SBP; and m 
= maximum SBP level.
We will calculate the number of  deaths from CVDs 
that is attributable to salt consumption by multiplying its 
PAF by total deaths (from CVDs) in each province-age-
sex stratum from 1990 to 2016.
11. Uncertainty Calculation for All Summary Measures
We will estimate the uncertainty of  the number of  deaths 
attributable to salt consumption (as will cause by sampling 
variability) using simulation analysis. To compute 
sampling uncertainty, we will use a simulation approach 
(1000 draws for each) to combine the uncertainties of  salt 
consumption distributions, its effect on blood pressure, 
RRs, and CVDs mortality rates in each province-age-
sex group (characterize by its mean and SD). We will 
incorporate sampling and non-sampling errors into final 
interval estimations.
Discussion
Although the importance of  reducing salt consumption 
to less than 5 g/d is emphasized,34 achieving this goal 
needs further efforts. These efforts could not lead to 
any result without accurate and coherent planning. Since 
a 30% relative reduction in mean population intake of 
salt/sodium is an important target of  WHO global action 
plan,36 the WHO advised ministers of  health and national 
mandated agencies to develop population-wide policies 
and use all the available tools to ensure their effective 
actions.34 In this regard, the Iranian action plan was 
prepared with a target of  4.30% relative reduction in the 
average salt intake in the population.37 To achieve these 
targets, the dietary salt reduction program is the simplest 
and most cost effective pathway to decrease the burden 
of  NCDs in developed and developing countries.38 
Such reductions have been achieved in China, Jamaica, 
and Nigeria.39,40 Many countries, including the United 
Kingdom, Finland, Japan, and Portugal, have reduced 
population-wide salt consumption through public 
education, collaboration with the food industry and 
implementing regulations on the salt content in foods.41 
In this setting, Finland observed a significant reduction in 
salt intake of  the Finnish population, from an average of 
approximately 12 g/d in 1979 to less than 9 g/d in 2002 
as measured by 24 hours urinary sodium.42 
Implementing health policies without planning and 
information can lead to waste of  resources. We hope that 
the results of  this study not only determine the necessity 
of  health policy makers’ actions in this field, but also 
direct them to more urgent population. 
The primary outcome of  this study is to determine 
mortality from CVDs attributable to salt consumption 
in Iran. As mentioned, achieving this outcome involves 
several steps that yield valuable information. One could 
be trend of  salt consumption over time. In addition 
to health system plans, numerous interventions like 
informing people, changes in life styles and diet and aging 
population could affect the trend of  salt consumption. 
Our results provide this opportunity for other researchers 
in this field to study the significance and magnitude of 
each factor by time, location, age and sex. 
On the other hand, several studies have measured the 
mean of  salt consumption among Iranian population. 
Moreover, some of  them have extended their scope at 
national and subnational levels at the same time. Beside 
geographical expansion of  our estimations, we believe 
that results can be representative of  all Iranian population 
in all period of  study. For instance, separate studies have 
been conducted in Tehran,15 Yazd,16 Ilam,18 Sari and 
Rasht.17 These studies just represent population of  some 
cites of  Iran and their information was collected in small 
cross-sectional studies. Although some cohort studies 
have collected food and salt data (such as TLGS, GCS, 
and so on), because of  population of  interest and basic 
outcome of  these studies, they should be considered 
with more caution. Also, some nutritional studies have 
been conducted in Iran nationally,43,44 but these studies 
have collected data in some specific years and are not 
representative for all years surveyed in our study.
Our approach focuses on collecting all available data 
sources including cohorts, cross-sectional, population 
based case-control studies and national representative 
surveys like Comprehensive Study on Household 
Food Consumption Patterns and STEPs studies, then 
using professional statistical modeling to extrapolate 
and interpolate the estimations. Gathering all available 
information could guarantee the reliability and precision 
of  results. Our data gathering is not limited to salt 
consumption and we have a plan to use relevant proxy 
of  consumption like household income expenditure 
survey (HIEs) and related covariates. The last advantage 
of  this study is the support of  NASBOD project team so 
that much information like death mortality rate is easily 
available.
In addition to all mentioned advantages, we face some 
issues. The main problem which could arise in this project 
is data scarcity in some years and provinces. Another 
problem could be the collaboration of  other researchers 
in sharing data from their studies. 
In conclusion, it seems that the results of  this study 
might be helpful for better detection of  CVDs mortality 
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attributable to salt consumption at national and 
subnational levels. Therefore, these findings provide good 
information about salt consumption and CVDs mortality 
attributable to it for policymakers in directing future 
policy decisions and planning cost-effective strategies in 
Iran.
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